300 related articles for article (PubMed ID: 28708672)
1. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
[TBL] [Abstract][Full Text] [Related]
2. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.
Lee SO; Lou W; Hou M; Onate SA; Gao AC
Oncogene; 2003 Sep; 22(39):7981-8. PubMed ID: 12970746
[TBL] [Abstract][Full Text] [Related]
4. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
5. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells.
Varisli L; Gonen-Korkmaz C; Syed HM; Bogurcu N; Debelec-Butuner B; Erbaykent-Tepedelen B; Korkmaz KS
Mol Cell Endocrinol; 2012 Mar; 350(1):107-17. PubMed ID: 22155408
[TBL] [Abstract][Full Text] [Related]
6. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
[TBL] [Abstract][Full Text] [Related]
7. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor levels are upregulated by Akt in prostate cancer.
Ha S; Ruoff R; Kahoud N; Franke TF; Logan SK
Endocr Relat Cancer; 2011 Apr; 18(2):245-55. PubMed ID: 21317204
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
10. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.
Li B; Lu W; Yang Q; Yu X; Matusik RJ; Chen Z
Prostate; 2014 Apr; 74(4):421-32. PubMed ID: 24347472
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.
Lin HK; Wang L; Hu YC; Altuwaijri S; Chang C
EMBO J; 2002 Aug; 21(15):4037-48. PubMed ID: 12145204
[TBL] [Abstract][Full Text] [Related]
12. AR-v7 protein expression is regulated by protein kinase and phosphatase.
Li Y; Xie N; Gleave ME; Rennie PS; Dong X
Oncotarget; 2015 Oct; 6(32):33743-54. PubMed ID: 26378044
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
15. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
Mediwala SN; Sun H; Szafran AT; Hartig SM; Sonpavde G; Hayes TG; Thiagarajan P; Mancini MA; Marcelli M
Prostate; 2013 Feb; 73(3):267-77. PubMed ID: 22821817
[TBL] [Abstract][Full Text] [Related]
16. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
17. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.
Fang Z; Zhang T; Dizeyi N; Chen S; Wang H; Swanson KD; Cai C; Balk SP; Yuan X
J Biol Chem; 2012 Jan; 287(3):2090-8. PubMed ID: 22139837
[TBL] [Abstract][Full Text] [Related]
19. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
Choy MK; Movassagh M; Bennett MR; Foo RS
J Cell Physiol; 2010 Mar; 222(3):635-9. PubMed ID: 19950214
[TBL] [Abstract][Full Text] [Related]
20. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
